<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387308</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00018</org_study_id>
    <nct_id>NCT01387308</nct_id>
  </id_info>
  <brief_title>Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets</brief_title>
  <official_title>An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study in healthy males to assess bioavailability of 4 different fostamatinib tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the relative bioavailability of R406 in healthy volunteers when fostamatinib is administered as a reformulated 100-mg tablet versus 2 x 50-mg tablets (Phase III formulation)</measure>
    <time_frame>From Pre-dose until 96 hours post dose of each treatment period</time_frame>
    <description>Assessments will include but is not limited to: plasma R406 AUC, Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the relative bioavailability of R406 in healthy volunteers when fostamatinib is administered as a reformulated 150-mg tablet versus 3 x 50-mg tablets (Phase III formulation)</measure>
    <time_frame>From pre-dose until 96 hours post dose of each treatment period</time_frame>
    <description>Assessments will include but is not limited to: plasma R406 AUC, Cmax )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of fostamatinib 50 mg, 100 mg, and 150 mg tablet batches</measure>
    <time_frame>From pre-dose until 96 hours post dose of each treatment period</time_frame>
    <description>The safety endpoints will include adverse event monitoring, vital signs, physical examinations, clinical laboratory tests, ECGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the within subject variability in R406 exposure when fostamatinib 50 mg tablets are administered on 2 separate occasions.</measure>
    <time_frame>From pre-dose until 96 hours post dose of each treatment period</time_frame>
    <description>Assessments will include but is not limited to: plasma R406 plasma AUC0-t, t1/2, and tmax</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 50 mg tablet x 2 (Phase 3 batch)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Fostamatinib 50 mg tablet x 3 (Phase 3 batch)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 100 mg tablet (new formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 150 mg tablet (new formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 50 mg tablet x 2 (Phase 3 batch)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 50 mg x 2, single dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 50 mg x 3, single dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 100 mg, single dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 150 mg, single dose</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 50 mg x 2, single dose</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent prior to any study specific procedures

          -  Volunteers will be males aged 18 to 55 years and with a weight of at least 50 kg and
             body mass index (BMI) between 18 and 30 kg/m2 inclusive

          -  Volunteers agreeing to participate in the optional genetic research must provide a
             separate, signed, written and dated informed consent for genetic research. The
             volunteer will not be excluded from other aspects of the study described in this
             Clinical Study Protocol so long as they consent to them

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of investigational product

          -  Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day

          -  Any clinically significant abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy male volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>fostamatinib</keyword>
  <keyword>Scientific Terminology: Bioavailability, R406 plasma AUC and C_maxR406 plasma AUC0-t, t1/2Î»z and t_max</keyword>
  <keyword>Laymen Terminology: Amount of R406 in blood</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

